FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 192 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or... March 25, 2026 Assisted Reproduction Treatments are Safe in Young Breast Cancer Survivors with... May 15, 2024 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Making Cancer Care More Equitable: A Cancer Survivor’s Story July 12, 2023 Load more HOT NEWS Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up How to Discuss Your Goals of Care With Your Cancer Care... Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal... Nursing Professor Who Used Her Breast Cancer Diagnosis as a Teaching...
